Efficacy Makes Sacituzumab Govitecan ‘Attractive’ in Advanced Breast Cancer


An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Data from the phase 3 TROPiCS-02 trial (NCT03901339) indicated that sacituzumab govitecan (Trodelvy) yielded various improvements in efficacy compared with chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

CancerNetwork® spoke with Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, ahead of the FDA’s approval of sacituzumab govitecan about data supporting the agency’s action.1

In the TROPiCS-02 trial, there was a median progression-free survival (PFS) of 5.5 months (95% CI, 4.2-7.0) in the sacituzumab arm compared with 4.0 months (95% CI, 3.1-4.4) in the chemotherapy arm (HR, 0.789; 95% CI, 0.646-0.964; P = .02).2 Additionally, the median overall survival (OS) was 14.4 months vs 11.2 months in each respective cohort (HR, 0.789; 95% CI, 0.646-0.964; P = .02).3

Tolaney noted the value of the improvements made in efficacy among patients treated with sacituzumab. “[The data] makes [sacituzumab] a really attractive agent for this patient population,” she said.


TROPiCS-02 had really explored sacituzumab govitecan in patients who were very heavily pretreated. They had had a prior CDK4/6 inhibitor, they had had a minimum of 2 lines of chemotherapy in the advanced disease setting, and could have received up to 4 lines of chemotherapy, so they had a median of 3 [lines of chemotherapy previously received]. [Patients were] very heavily pretreated, and patients had been randomized to get sacituzumab or to get treatment of physician's choice chemotherapy. What we saw was that sacituzumab not only improved progression-free survival but, in fact, led to statistically significant improvement in overall survival, as well as significant improvement in objective response rate. What we're seeing is that this agent does perform better than chemotherapy in this population all around in terms of response, PFS, and OS. And so I think it makes it a really attractive agent for this patient population.


  1. U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed February 3, 2023. https://bwnews.pr/3Y0bftX
  2. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365-3376. doi:10.1200/JCO.22.01002
  3. Rugo HS, Bardia A, Marme F, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol. 2022;33(suppl 7):S808-S869. doi:10.1016/annonc/annonc1089
Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content